BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia

M.S. Zabriskie, C.A. Eide, S.K. Tantravahi, N.A. Vellore, J. Estrada, F.E. Nicolini, H.J. Khoury, R.A. Larson, M. Konopleva, J.E. Cortes, H. Kantarjian, E.J. Jabbour, S.M. Kornblau, J.H. Lipton, D. Rea, L. Stenke, G. Barbany, T. de Lange, J.C. Hernandez-Boluda, G.J. OssenkoppeleR.D. Press, C. Chuah, S.L. Goldberg, M. Wetzler, F.X. Mahon, G. Etienne, M. Baccarani, S. Soverini, G. Rosti, P. Rousselot, R. Friedman, M. Deininger, K.R. Reynolds, W.L. Heaton, A.M. Eiring, A.D. Pomicter, J.S. Khorashad, T.W. Kelley, R. Baron, B.J. Druker, M.W. Deininger, T. O'Hare

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)428-442
JournalCancer Cell
Volume26
Issue number3
DOIs
Publication statusPublished - 2014

Cite this